Breaking News

Novella Clinical Names European and Asian Ops Director

By Kristin Brooks | March 11, 2014

Smyth brings more than 20 years of R&D experience

Chris Smyth, Ph.D., MBA has been appointed managing director of European and Asian operations at Novella Clinical, a Quintiles company. Dr. Smyth will be based in Novella’s European headquarters in Stevenage, England, and will provide strategic leadership, organization and training resources for the company’s regional teams. Dr. Smyth will also lead oncology delivery operations in all markets outside the U.S. He succeeds Elizabeth Edwards, who will now serve as executive vice president of global operations, overseeing Novella’s clinical monitoring division.
 
Dr. Smyth has more than 20 years of R&D experience, having led CROs and biopharma companies in Europe and the U.S., dealing exclusively in hematology and oncology drug development since 2003. He joins the company from INC Research, where he served as senior vice president of clinical development in the oncology division.
 
“We are fortunate to have someone as experienced as Dr. Smyth guiding our team and business objectives in Europe and Asia,” said Novella Clinical Chief Operating Officer Rob King. “His depth of international leadership and oncology operations expertise will prove to be an invaluable resource as we continue to expand our services into new markets.”
  • When Quality Meets Confidence

    When Quality Meets Confidence

    Dr. Fadia AlKhalil, Vice President of Global Business Development for Laboratory Services, SGS ||November 9, 2016
    A look at global account management for R&D outsourcing

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus